Beam Therapeutics (BEAM) Competitors $19.93 +0.22 (+1.12%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BEAM vs. ROIV, LNTH, RVMD, BBIO, LEGN, TGTX, TLX, BPMC, SRPT, and AXSMShould you be buying Beam Therapeutics stock or one of its competitors? The main competitors of Beam Therapeutics include Roivant Sciences (ROIV), Lantheus (LNTH), Revolution Medicines (RVMD), BridgeBio Pharma (BBIO), Legend Biotech (LEGN), TG Therapeutics (TGTX), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Blueprint Medicines (BPMC), Sarepta Therapeutics (SRPT), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical products" industry. Beam Therapeutics vs. Roivant Sciences Lantheus Revolution Medicines BridgeBio Pharma Legend Biotech TG Therapeutics Telix Pharmaceuticals Limited American Depositary Shares Blueprint Medicines Sarepta Therapeutics Axsome Therapeutics Beam Therapeutics (NASDAQ:BEAM) and Roivant Sciences (NASDAQ:ROIV) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, community ranking, valuation, earnings, risk and dividends. Which has more volatility & risk, BEAM or ROIV? Beam Therapeutics has a beta of 2.02, meaning that its stock price is 102% more volatile than the S&P 500. Comparatively, Roivant Sciences has a beta of 1.25, meaning that its stock price is 25% more volatile than the S&P 500. Do analysts prefer BEAM or ROIV? Beam Therapeutics currently has a consensus price target of $49.45, indicating a potential upside of 147.77%. Roivant Sciences has a consensus price target of $17.50, indicating a potential upside of 50.86%. Given Beam Therapeutics' higher probable upside, analysts plainly believe Beam Therapeutics is more favorable than Roivant Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Beam Therapeutics 0 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 3.00Roivant Sciences 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has stronger valuation and earnings, BEAM or ROIV? Roivant Sciences has higher revenue and earnings than Beam Therapeutics. Roivant Sciences is trading at a lower price-to-earnings ratio than Beam Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBeam Therapeutics$63.52M31.60-$132.53M-$4.58-4.36Roivant Sciences$122.59M67.52$4.35B-$0.15-77.33 Do insiders & institutionals have more ownership in BEAM or ROIV? 99.7% of Beam Therapeutics shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 4.2% of Beam Therapeutics shares are held by insiders. Comparatively, 7.9% of Roivant Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the MarketBeat Community favor BEAM or ROIV? Beam Therapeutics received 11 more outperform votes than Roivant Sciences when rated by MarketBeat users. However, 78.57% of users gave Roivant Sciences an outperform vote while only 58.93% of users gave Beam Therapeutics an outperform vote. CompanyUnderperformOutperformBeam TherapeuticsOutperform Votes6658.93% Underperform Votes4641.07% Roivant SciencesOutperform Votes5578.57% Underperform Votes1521.43% Is BEAM or ROIV more profitable? Beam Therapeutics has a net margin of -41.07% compared to Roivant Sciences' net margin of -119.54%. Roivant Sciences' return on equity of -14.05% beat Beam Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Beam Therapeutics-41.07% -16.22% -10.94% Roivant Sciences -119.54%-14.05%-12.81% Does the media favor BEAM or ROIV? In the previous week, Roivant Sciences had 7 more articles in the media than Beam Therapeutics. MarketBeat recorded 15 mentions for Roivant Sciences and 8 mentions for Beam Therapeutics. Roivant Sciences' average media sentiment score of 1.35 beat Beam Therapeutics' score of 0.41 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Roivant Sciences 13 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive SummaryBeam Therapeutics and Roivant Sciences tied by winning 9 of the 18 factors compared between the two stocks. Get Beam Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BEAM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BEAM vs. The Competition Export to ExcelMetricBeam TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.01B$2.98B$5.54B$7.74BDividend YieldN/A1.89%5.11%4.22%P/E Ratio-11.3430.3022.4118.43Price / Sales31.60495.68393.33103.32Price / CashN/A168.6838.1834.62Price / Book1.663.186.724.23Net Income-$132.53M-$72.35M$3.22B$248.23M7 Day Performance0.38%3.00%2.83%2.95%1 Month Performance-10.13%-0.35%-0.36%2.11%1 Year Performance-5.94%-21.54%17.84%5.31% Beam Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BEAMBeam Therapeutics3.0252 of 5 stars$19.93+1.1%$49.45+148.1%-10.6%$2.00B$63.52M-11.32510Upcoming EarningsShort Interest ↑Gap DownROIVRoivant Sciences2.1639 of 5 stars$10.04-1.1%$17.50+74.3%+1.4%$7.16B$122.59M-66.93860Positive NewsLNTHLantheus3.9632 of 5 stars$100.62-0.7%$129.43+28.6%+54.6%$6.89B$1.53B16.74700Upcoming EarningsNews CoveragePositive NewsRVMDRevolution Medicines3.7672 of 5 stars$36.56-0.5%$66.67+82.3%+9.6%$6.80B$742,000.00-10.18250Upcoming EarningsAnalyst ForecastNews CoveragePositive NewsBBIOBridgeBio Pharma4.5442 of 5 stars$33.51-1.1%$53.00+58.2%+43.0%$6.37B$221.90M-11.76400Earnings ReportAnalyst ForecastOptions VolumeNews CoverageGap UpLEGNLegend Biotech2.6245 of 5 stars$32.24-1.7%$79.00+145.0%-23.7%$5.92B$627.24M-33.941,070Positive NewsTGTXTG Therapeutics3.3312 of 5 stars$36.97-3.5%$40.67+10.0%+229.3%$5.81B$329.00M-369.66290Upcoming EarningsNews CoveragePositive NewsGap DownTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$16.21-3.0%$22.00+35.7%N/A$5.48B$783.21M0.00N/AAnalyst RevisionNews CoverageGap DownBPMCBlueprint Medicines2.5612 of 5 stars$84.18-0.6%$124.95+48.4%-5.0%$5.38B$508.82M-77.94640Upcoming EarningsAnalyst ForecastNews CoveragePositive NewsSRPTSarepta Therapeutics4.7339 of 5 stars$55.23+2.7%$158.70+187.3%-52.8%$5.36B$1.90B44.18840AXSMAxsome Therapeutics4.8294 of 5 stars$103.00-1.4%$169.80+64.9%+49.2%$5.02B$385.69M-17.20380Upcoming EarningsAnalyst ForecastShort Interest ↓Positive News Related Companies and Tools Related Companies ROIV Alternatives LNTH Alternatives RVMD Alternatives BBIO Alternatives LEGN Alternatives TGTX Alternatives TLX Alternatives BPMC Alternatives SRPT Alternatives AXSM Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BEAM) was last updated on 4/30/2025 by MarketBeat.com Staff From Our Partners"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredTop performing AI play of the decade…? (The answer will shock you)You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | SponsoredChina’s next move could destroy U.S. techThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Beam Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Beam Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BEAM Stock Free BEAM Stock Alerts